_id
6915f77dbc934aba376b24e3
Ticker
SGMT
Name
Sagimet Biosciences Inc. Series A Common Stock
Exchange
NASDAQ
Address
155 Bovet Road, San Mateo, CA, United States, 94402
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.sagimet.com
Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Last Close
5.56
Volume
295631
Current Price
6.26
Change
-0.08
Last Updated
2026-01-07T11:39:02.586Z
Image
data:image/webp;base64,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
Ipo Date
2023-07-14T00:00:00.000Z
Market Cap
177567936
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.93075
Sentiment Sources
4
Rating
4.7143
Target Price
28.1429
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
14334000
Operating Income
-14334000
Interest Expense
-
Pretax Income
-12908000
Net Income
-12908000
Eps
-0.3975987230267477
Dividends Per Share
-
Shares Outstanding
31001109
Income Tax Expense
-
EBITDA
-12908000
Operating Margin
-
Total Other Income Expense Net
1426000
Cash
32496000
Short Term Investments
84197000
Receivables
-
Inventories
-
Total Current Assets
119233000
Property Plant Equipment
115000
Total Assets
128401000
Payables
4243000
Short Term Debt
115000
Long Term Debt
-
Total Liabilities
9146000
Equity
119255000
Bs_currency_symbol
USD
Depreciation
-
Change In Working Capital
701000
Cash From Operations
-10180000
Capital Expenditures
0
Cash From Investing
75000
Cash From Financing
274000
Net Change In Cash
-9831000
Cf_currency_symbol
USD
PE
-
PB
1.7041652775984235
ROE
-10.823864827470546
ROA
-10.052881208090279
FCF
-10180000
Fcf Percent
-
Piotroski FScore
1
Health Score
43
Deep Value Investing Score
4.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
14334000
Quarters > 0 > income Statement > operating Income
-14334000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-12908000
Quarters > 0 > income Statement > net Income
-12908000
Quarters > 0 > income Statement > eps
-0.3975987230267477
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
32464893
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-12908000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
1426000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
32496000
Quarters > 0 > balance Sheet > short Term Investments
84197000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
119233000
Quarters > 0 > balance Sheet > property Plant Equipment
115000
Quarters > 0 > balance Sheet > total Assets
128401000
Quarters > 0 > balance Sheet > payables
4243000
Quarters > 0 > balance Sheet > short Term Debt
115000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
9146000
Quarters > 0 > balance Sheet > equity
119255000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-12908000
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
701000
Quarters > 0 > cash Flow > cash From Operations
-10180000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
75000
Quarters > 0 > cash Flow > cash From Financing
274000
Quarters > 0 > cash Flow > net Change In Cash
-9831000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.3975987230267477
Quarters > 0 > ratios > PB
1.7041652775984235
Quarters > 0 > ratios > ROE
-10.823864827470546
Quarters > 0 > ratios > ROA
-10.052881208090279
Quarters > 0 > ratios > FCF
-10180000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
43
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
11925000
Quarters > 1 > income Statement > operating Income
-11925000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-10386000
Quarters > 1 > income Statement > net Income
-10386000
Quarters > 1 > income Statement > eps
-0.3225930091926894
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
32195366
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-11925000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
1539000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
42327000
Quarters > 1 > balance Sheet > short Term Investments
83080000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
127196000
Quarters > 1 > balance Sheet > property Plant Equipment
152000
Quarters > 1 > balance Sheet > total Assets
137407000
Quarters > 1 > balance Sheet > payables
1921000
Quarters > 1 > balance Sheet > short Term Debt
152000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
7247000
Quarters > 1 > balance Sheet > equity
130160000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-10386000
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
-125000
Quarters > 1 > cash Flow > cash From Operations
-9101000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-13290000
Quarters > 1 > cash Flow > cash From Financing
1000
Quarters > 1 > cash Flow > net Change In Cash
-22390000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.3225930091926894
Quarters > 1 > ratios > PB
1.548424947449293
Quarters > 1 > ratios > ROE
-7.97940995697603
Quarters > 1 > ratios > ROA
-7.5585668852387435
Quarters > 1 > ratios > FCF
-9101000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
43
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
19865000
Quarters > 2 > income Statement > operating Income
-19865000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-18176000
Quarters > 2 > income Statement > net Income
-18176000
Quarters > 2 > income Statement > eps
-0.5645536645126803
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
32195345
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-19865000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
1689000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
64717000
Quarters > 2 > balance Sheet > short Term Investments
79852000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
146072000
Quarters > 2 > balance Sheet > property Plant Equipment
38000
Quarters > 2 > balance Sheet > total Assets
146172000
Quarters > 2 > balance Sheet > payables
3223000
Quarters > 2 > balance Sheet > short Term Debt
39000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
7180000
Quarters > 2 > balance Sheet > equity
138992000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-18176000
Quarters > 2 > cash Flow > depreciation
-
Quarters > 2 > cash Flow > change In Working Capital
-726000
Quarters > 2 > cash Flow > cash From Operations
-14536000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
3413000
Quarters > 2 > cash Flow > cash From Financing
0
Quarters > 2 > cash Flow > net Change In Cash
-11123000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.5645536645126803
Quarters > 2 > ratios > PB
1.4500320860193392
Quarters > 2 > ratios > ROE
-13.077011626568435
Quarters > 2 > ratios > ROA
-12.434666009906138
Quarters > 2 > ratios > FCF
-14536000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
43
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
18195000
Quarters > 3 > income Statement > operating Income
-18195000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-16201000
Quarters > 3 > income Statement > net Income
-16201000
Quarters > 3 > income Statement > eps
-0.5032093925379585
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
32195345
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-16201000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
1994000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
75840000
Quarters > 3 > balance Sheet > short Term Investments
75410000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
152774000
Quarters > 3 > balance Sheet > property Plant Equipment
77000
Quarters > 3 > balance Sheet > total Assets
160259000
Quarters > 3 > balance Sheet > payables
1425000
Quarters > 3 > balance Sheet > short Term Debt
78000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
4454000
Quarters > 3 > balance Sheet > equity
155805000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-16201000
Quarters > 3 > cash Flow > depreciation
-
Quarters > 3 > cash Flow > change In Working Capital
3662000
Quarters > 3 > cash Flow > cash From Operations
-11024000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
9850000
Quarters > 3 > cash Flow > cash From Financing
0
Quarters > 3 > cash Flow > net Change In Cash
-1174000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.5032093925379585
Quarters > 3 > ratios > PB
1.2935583562786817
Quarters > 3 > ratios > ROE
-10.398254228041463
Quarters > 3 > ratios > ROA
-10.10926063434815
Quarters > 3 > ratios > FCF
-11024000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
43
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
54454000
Annuals > 0 > income Statement > operating Income
-54454000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-45567000
Annuals > 0 > income Statement > net Income
-45567000
Annuals > 0 > income Statement > eps
-1.4534592102734467
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
31350725
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-45567000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
8887000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
75840000
Annuals > 0 > balance Sheet > short Term Investments
75410000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
152774000
Annuals > 0 > balance Sheet > property Plant Equipment
77000
Annuals > 0 > balance Sheet > total Assets
160259000
Annuals > 0 > balance Sheet > payables
1425000
Annuals > 0 > balance Sheet > short Term Debt
78000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
4454000
Annuals > 0 > balance Sheet > equity
155805000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-45567000
Annuals > 0 > cash Flow > depreciation
-
Annuals > 0 > cash Flow > change In Working Capital
-1048000
Annuals > 0 > cash Flow > cash From Operations
-42435000
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-61683000
Annuals > 0 > cash Flow > cash From Financing
104819000
Annuals > 0 > cash Flow > net Change In Cash
701000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-1.4534592102734467
Annuals > 0 > ratios > PB
1.0986486858573217
Annuals > 0 > ratios > ROE
-29.246173100991623
Annuals > 0 > ratios > ROA
-28.433348517087964
Annuals > 0 > ratios > FCF
-42435000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
2000000
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
2000000
Annuals > 1 > income Statement > operating Expenses
32740000
Annuals > 1 > income Statement > operating Income
-30740000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-27876000
Annuals > 1 > income Statement > net Income
-27876000
Annuals > 1 > income Statement > eps
-1.5320960267401211
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
18194682
Annuals > 1 > income Statement > income Tax Expense
-2860000
Annuals > 1 > income Statement > EBITDA
-30740000
Annuals > 1 > income Statement > operating Margin
-1537
Annuals > 1 > income Statement > total Other Income Expense Net
2864000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
75139000
Annuals > 1 > balance Sheet > short Term Investments
19758000
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
96646000
Annuals > 1 > balance Sheet > property Plant Equipment
73000
Annuals > 1 > balance Sheet > total Assets
96719000
Annuals > 1 > balance Sheet > payables
186000
Annuals > 1 > balance Sheet > short Term Debt
65000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
5654000
Annuals > 1 > balance Sheet > equity
91065000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-27876000
Annuals > 1 > cash Flow > depreciation
30740000
Annuals > 1 > cash Flow > change In Working Capital
-978000
Annuals > 1 > cash Flow > cash From Operations
-23766000
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
12580000
Annuals > 1 > cash Flow > cash From Financing
86167000
Annuals > 1 > cash Flow > net Change In Cash
74981000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-1.5320960267401211
Annuals > 1 > ratios > PB
1.0909017044967881
Annuals > 1 > ratios > ROE
-30.611101960138363
Annuals > 1 > ratios > ROA
-28.821637940838922
Annuals > 1 > ratios > FCF
-23766000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-11.883
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
130000
Annuals > 2 > income Statement > gross Profit
-130000
Annuals > 2 > income Statement > operating Expenses
31055000
Annuals > 2 > income Statement > operating Income
-31055000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-30499000
Annuals > 2 > income Statement > net Income
-30499000
Annuals > 2 > income Statement > eps
-1.3754356102304377
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
22174066
Annuals > 2 > income Statement > income Tax Expense
-31608000
Annuals > 2 > income Statement > EBITDA
-31055000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
3000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
158000
Annuals > 2 > balance Sheet > short Term Investments
32187000
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
32792000
Annuals > 2 > balance Sheet > property Plant Equipment
212000
Annuals > 2 > balance Sheet > total Assets
33031000
Annuals > 2 > balance Sheet > payables
1125000
Annuals > 2 > balance Sheet > short Term Debt
133000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
219981000
Annuals > 2 > balance Sheet > equity
-186950000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-30499000
Annuals > 2 > cash Flow > depreciation
130000
Annuals > 2 > cash Flow > change In Working Capital
4214000
Annuals > 2 > cash Flow > cash From Operations
-24490000
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-32010000
Annuals > 2 > cash Flow > cash From Financing
-73000
Annuals > 2 > cash Flow > net Change In Cash
-56573000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-1.3754356102304377
Annuals > 2 > ratios > PB
-0.6476084533832576
Annuals > 2 > ratios > ROE
16.313987697245253
Annuals > 2 > ratios > ROA
-92.33447367624353
Annuals > 2 > ratios > FCF
-24490000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
27
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
134000
Annuals > 3 > income Statement > gross Profit
-134000
Annuals > 3 > income Statement > operating Expenses
23719000
Annuals > 3 > income Statement > operating Income
-23719000
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-24442000
Annuals > 3 > income Statement > net Income
-24442000
Annuals > 3 > income Statement > eps
-1.102278670948305
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
22174066
Annuals > 3 > income Statement > income Tax Expense
-23745000
Annuals > 3 > income Statement > EBITDA
-23719000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-749000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
56731000
Annuals > 3 > balance Sheet > short Term Investments
0
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
58663000
Annuals > 3 > balance Sheet > property Plant Equipment
342000
Annuals > 3 > balance Sheet > total Assets
59032000
Annuals > 3 > balance Sheet > payables
761000
Annuals > 3 > balance Sheet > short Term Debt
124000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
217291000
Annuals > 3 > balance Sheet > equity
-158259000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-24442000
Annuals > 3 > cash Flow > depreciation
134000
Annuals > 3 > cash Flow > change In Working Capital
-55000
Annuals > 3 > cash Flow > cash From Operations
-21710000
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
9739000
Annuals > 3 > cash Flow > net Change In Cash
-11971000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-1.102278670948305
Annuals > 3 > ratios > PB
-0.765014314257009
Annuals > 3 > ratios > ROE
15.444303325561263
Annuals > 3 > ratios > ROA
-41.404661878303294
Annuals > 3 > ratios > FCF
-21710000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
26
Valuation > metrics > PE
-0.3975987230267477
Valuation > metrics > PB
1.7041652775984235
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-10.823864827470546
Profitability > metrics > ROA
-10.825861967743828
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.0766928011404134
Risk > final Score
80
Risk > verdict
Low
Liquidity > metrics > Current Ratio
27.359568609453877
Liquidity > metrics > Quick Ratio
27.359568609453877
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
29
Prev Risks > 1
13
Prev Risks > 2
80
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-22T21:16:36.939Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-13
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.4
Earnings History > 0 > eps Estimate
-1.04
Earnings History > 0 > eps Difference
0.64
Earnings History > 0 > surprise Percent
61.5385
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-13
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.32
Earnings History > 1 > eps Estimate
-0.88
Earnings History > 1 > eps Difference
0.56
Earnings History > 1 > surprise Percent
63.6364
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-08
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.56
Earnings History > 2 > eps Estimate
-0.71
Earnings History > 2 > eps Difference
0.15
Earnings History > 2 > surprise Percent
21.1268
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-12
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.5
Earnings History > 3 > eps Estimate
-0.49
Earnings History > 3 > eps Difference
-0.01
Earnings History > 3 > surprise Percent
-2.0408
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-14
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.45
Earnings History > 4 > eps Estimate
-0.55
Earnings History > 4 > eps Difference
0.1
Earnings History > 4 > surprise Percent
18.1818
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-15
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.25
Earnings History > 5 > eps Estimate
-0.5
Earnings History > 5 > eps Difference
0.25
Earnings History > 5 > surprise Percent
50
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-15
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.23
Earnings History > 6 > eps Estimate
-0.4
Earnings History > 6 > eps Difference
0.17
Earnings History > 6 > surprise Percent
42.5
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-03-25
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.78
Earnings History > 7 > eps Estimate
-0.58
Earnings History > 7 > eps Difference
-0.2
Earnings History > 7 > surprise Percent
-34.4828
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-11-13
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.35
Earnings History > 8 > eps Estimate
-0.99
Earnings History > 8 > eps Difference
0.64
Earnings History > 8 > surprise Percent
64.6465
Earnings History > 9 > period
2023-06-30
Earnings History > 9 > report Date
2023-08-21
Earnings History > 9 > date
2023-06-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-35.8
Earnings History > 9 > eps Estimate
-0.5
Earnings History > 9 > eps Difference
-35.3
Earnings History > 9 > surprise Percent
-7060
Earnings History > 10 > period
2023-03-31
Earnings History > 10 > report Date
2023-05-31
Earnings History > 10 > date
2023-03-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.44
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
-0.44
Earnings History > 10 > surprise Percent
-
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ATreasury Yields: Can SGMT generate free cash flow - July 2025 Spike Watch & Fast Entry and Exit Trade Plans baoquankhu1.vn
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$28.1429
Analyst Picks
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Sagimet Biosciences Inc. Series A Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.4
EPS Estimate
-1.04
EPS Difference
0.64
Surprise Percent
61.5385%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.